Abstract | IMPORTANCE OF THE FIELD:
Cancer patients are at increased risk of developing venous thromboembolism (VTE). The occurrence of VTE predicts worse prognosis in cancer patients: whereas the 1-year survival in cancer patients free of thrombosis is 36%, in patients with diagnosed VTE it is 12%. The management of VTE in cancer patients is challenging because the anticoagulant treatment in these patients can be less effective and carry considerable morbidity. AREAS COVERED IN THIS REVIEW: This review covers the treatment strategies for cancer patients with VTE and highlights the new anticoagulant agents and their potential use in oncology. In writing this review, a literature search was performed using the PUB MED database with the following subject headings: cancer, venous thromboembolism and anticoagulant treatment. WHAT THE READER WILL GAIN: TAKE HOME MESSAGE:
|
Authors | Marina Panova-Noeva, Anna Falanga |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 12
Pg. 2049-58
(Aug 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20642371
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticoagulants
- Fibrinolytic Agents
|
Topics |
- Adult
- Anticoagulants
(therapeutic use)
- Blood Coagulation
(drug effects)
- Child
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Neoplasms
(blood, complications)
- Time Factors
- Treatment Outcome
- Venous Thromboembolism
(blood, drug therapy, etiology)
|